Mitsubishi Tanabe Pharma Corporation revised earnings guidance for the six months ended September 30, 2016 and year ending March 31, 2017. For the six months, the company expects revenue of JPY 204,000 million, operating profit of JPY 47,500 million, profit before tax of JPY 49,000 million and net profit attributable to owners of the company of JPY 36,000 million or JPY 64.17 per share against previously expected revenue of JPY 193,000 million, operating profit of JPY 38,000 million, profit before tax of JPY 38,500 million and net profit attributable to owners of the company of JPY 28,500 million or JPY 50.80 per share. The company expects that sales revenue surpasses the level of the previously announced forecast due to favorable domestic sales of main products; Simponi, and vaccines, extra. For the year ending March 31, 2017, the company expects revenue of JPY 414,000 million, operating profit of JPY 84,000 million, profit before tax of JPY 86,000 million and net profit attributable to owners of the company of JPY 64,000 million or JPY 114.08 per share against previously expected revenue of JPY 406,500 million, operating profit of JPY 75,500 million, profit before tax of JPY 77,000 million and net profit attributable to owners of the company of JPY 57,000 million or JPY 101.61 per share.